Perseus Biomics

Active

Private limited companyfounded 2016active for 10 yearsGaston Geenslaan 3, 3001 Leuven, Belgium14 active companies are registered at this addressKBO/BCE: BE 0650.946.412

Summary

The computed 12-month bankruptcy probability of Perseus Biomics is 2.2% (moderate). The annual accounts of Perseus Biomics for financial year 2025 show a net loss of 54% of the equity at the start of that year. The 2025 annual accounts show equity of €2.1m and a net result of -€2.5m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 45% of 60 sector peers (NACE 21, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

Perseus BiomicsActiveChecked score 52/100

Risk analysis Report Compare

Activity

Manufacture of basic pharmaceutical products and pharmaceutical preparations

NACE 21100Research and development on biotechnology NACE 72101

5th largest company by total assets in Flemish Brabant, Pharmaceuticals sector1 site

Size

€5.2mtotal assets 2025

Staff: 14.3 FTE
Equity: €2.1m
Loss: -€2.5m

Turnover not published (abbreviated or micro format)

Financial health

52 Fair Checked score 2025

Bankruptcy probabilitywithin 12 months: 2.2%

Structure

Holdings: 2

2025 accounts 2 days early4 of 11 deeds summarised

Why 52raises riskLoss of €2.5m, the second in a row (financial year 2025)Liquidity: current ratio 0.40, cash €56,555, halved1 change of registered office in 24 monthslowers riskFigures for financial year 2025 (filed 29-07-2026)Show the evidence

Checked score

Score 2025

52 / 100

Fair

Probability in this band: 1.5% to 4.2%

Financially better than 24% of its sector peers (NACE 21, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 64-36

equity 39.2% of total assets

Liquidity 43-13

short-term debt 22.9% · cash 1.1%

Profitability 0=

return on assets -47.0%

Bankruptcy probability, 12 months

2.2% Moderate

0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (43 companies, NACE 21, small)

Last 24 months 11-2024: 0.2%lowest value 12-2024: 0.2%● unchanged vs 11-2024lowest value 01-2025: 0.2%● unchanged vs 12-2024lowest value 02-2025: 0.2%● unchanged vs 01-2025lowest value 03-2025: 0.2%● unchanged vs 02-2025lowest value 04-2025: 0.5%▲ +0.3 percentage points vs 03-2025 05-2025: 0.6%▲ +0.1 percentage points vs 04-2025 06-2025: 0.6%● unchanged vs 05-2025 07-2025: 0.7%▲ +0.1 percentage points vs 06-2025 08-2025: 1.0%▲ +0.3 percentage points vs 07-2025 09-2025: 1.3%▲ +0.3 percentage points vs 08-2025 10-2025: 1.3%● unchanged vs 09-2025 11-2025: 1.3%● unchanged vs 10-2025 12-2025: 1.3%● unchanged vs 11-2025 01-2026: 1.3%● unchanged vs 12-2025 02-2026: 1.3%● unchanged vs 01-2026 03-2026: 1.3%● unchanged vs 02-2026 04-2026: 1.5%▲ +0.2 percentage points vs 03-2026 05-2026: 1.6%▲ +0.1 percentage points vs 04-2026 06-2026: 1.8%▲ +0.2 percentage points vs 05-2026 07-2026: 1.9%▲ +0.1 percentage points vs 06-2026 08-2026: 2.4%▲ +0.5 percentage points vs 07-2026highest value 09-2026: 2.2%▼ -0.2 percentage points vs 08-2026 10-2026: 2.2%● unchanged vs 09-2026

Credit of up to €100,000 on 30-day terms, only on tighter conditions

Net loss of at least half of total assets or of the equity at the start of the financial year.

Liquidity insufficient (current ratio 0.4, compared with 1.48 in 2024, below 1; short-term debt: 22.9% and cash: 1.1% of total assets), and 60.8% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small): better than 33% on solvency, 37% on liquidity, 14% on profitability and 12% on growth.

The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Loss of €2.5m, the second in a row (financial year 2025)

NBB · annual accounts

Liquidity: current ratio 0.40, cash €56,555, halved

NBB · annual accounts

1 change of registered office in 24 months

Belgian Official Gazette

Figures for financial year 2025 (filed 29-07-2026)

NBB · annual accounts

Persistent losses

Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.

NBB · annual accounts 2025

Net result per financial year

1819202122232425

2018 to 2025 · latest year -€2.5m

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.

NBB · 9 filings

Deviation from the deadline

2025

2 days early

2024

7 days late

2023

13 days early

2022

23 days late

2021

16 days early

2020

30 days late

2019

48 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 11 days after the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 July (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

26-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

29-07-2026 Annual accounts filedfinancial year 2025 · abbreviated…
31-12-2025 Weakest financial yearnet -€2.5m
15-09-2025 Resignation: ODC (Odyssey Development and Consulting)…Appointment: Walid Hanna (director) ·…

Key points

Risk: 8 loss-making years in a rowloss financial year 2025 -€2.5m View
Caution: Among the weakest 6% on net resultsector median -€11,123 · 60 companies -€2.5m View
Caution: Equity fell in 2025from €4.5m to €2.1m ▼ 54.5% View
EU research moneyEU contribution €3.2m View

By topic

Financials

Financial year: 2025
Total assets: €5.2m
Loss: -€2.5m
Solvency: 39.2%

Total assets▼ 4.0%

Net result

20182025

Go to Financials

Board & ownership

Board: 3 members

Adam Krzysztof ROLEWSKIDirector
Thomas PrischenkDirector
Johan HofkensDirector

Go to Board & ownership

Network & group

Subsidiaries: 1
Direct holdings: 2

2 holdings

Go to Network & group

Timeline

Events: 17
Since: 2018
Next accounts: by 31-07-2027

07-08-2025Annual accounts filed
21-03-2025Resignations: Theo Lasser (director) and Walid Hanna…
27-09-2024Appointment: Thomas Prischenk (director)

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100
Founded: 31-03-2016
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 2

See the provisions in the deeds

Go to Articles of association

Key facts about Perseus Biomics

What is the company number of Perseus Biomics?: 0650.946.412. In Belgium the VAT number is the company number with BE in front: BE 0650.946.412.
Where is Perseus Biomics based?: The registered office is at Gaston Geenslaan 3, 3001 Leuven.Company details
What does Perseus Biomics do?: According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
What is the legal form of Perseus Biomics?: Private limited company (BV).
When was Perseus Biomics founded?: On 31-03-2016.
Is Perseus Biomics still active?: Yes, Perseus Biomics is an active enterprise in the KBO register.
How many employees does Perseus Biomics have?: On average 14.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Perseus Biomics?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is Perseus Biomics profitable?: In financial year 2025, Perseus Biomics made a loss of €2.5m.
Where can I find the annual accounts of Perseus Biomics?: Perseus Biomics filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Perseus Biomics due?: By 31-07-2027, for financial year 2026.Timeline